Cargando…

Structural rearrangement of amyloid-β upon inhibitor binding suppresses formation of Alzheimer’s disease related oligomers

The formation of oligomers of the amyloid-β peptide plays a key role in the onset of Alzheimer's disease. We describe herein the investigation of disease-relevant small amyloid-β oligomers by mass spectrometry and ion mobility spectrometry, revealing functionally relevant structural attributes....

Descripción completa

Detalles Bibliográficos
Autores principales: Lieblein, Tobias, Zangl, Rene, Martin, Janosch, Hoffmann, Jan, Hutchison, Marie J, Stark, Tina, Stirnal, Elke, Schrader, Thomas, Schwalbe, Harald, Morgner, Nina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: eLife Sciences Publications, Ltd 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7682991/
https://www.ncbi.nlm.nih.gov/pubmed/33095161
http://dx.doi.org/10.7554/eLife.59306
_version_ 1783612788144340992
author Lieblein, Tobias
Zangl, Rene
Martin, Janosch
Hoffmann, Jan
Hutchison, Marie J
Stark, Tina
Stirnal, Elke
Schrader, Thomas
Schwalbe, Harald
Morgner, Nina
author_facet Lieblein, Tobias
Zangl, Rene
Martin, Janosch
Hoffmann, Jan
Hutchison, Marie J
Stark, Tina
Stirnal, Elke
Schrader, Thomas
Schwalbe, Harald
Morgner, Nina
author_sort Lieblein, Tobias
collection PubMed
description The formation of oligomers of the amyloid-β peptide plays a key role in the onset of Alzheimer's disease. We describe herein the investigation of disease-relevant small amyloid-β oligomers by mass spectrometry and ion mobility spectrometry, revealing functionally relevant structural attributes. In particular, we can show that amyloid-β oligomers develop in two distinct arrangements leading to either neurotoxic oligomers and fibrils or non-toxic amorphous aggregates. Comprehending the key-attributes responsible for those pathways on a molecular level is a pre-requisite to specifically target the peptide's tertiary structure with the aim to promote the emergence of non-toxic aggregates. Here, we show for two fibril inhibiting ligands, an ionic molecular tweezer and a hydrophobic peptide that despite their different interaction mechanisms, the suppression of the fibril pathway can be deduced from the disappearance of the corresponding structure of the first amyloid-β oligomers.
format Online
Article
Text
id pubmed-7682991
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher eLife Sciences Publications, Ltd
record_format MEDLINE/PubMed
spelling pubmed-76829912020-11-25 Structural rearrangement of amyloid-β upon inhibitor binding suppresses formation of Alzheimer’s disease related oligomers Lieblein, Tobias Zangl, Rene Martin, Janosch Hoffmann, Jan Hutchison, Marie J Stark, Tina Stirnal, Elke Schrader, Thomas Schwalbe, Harald Morgner, Nina eLife Neuroscience The formation of oligomers of the amyloid-β peptide plays a key role in the onset of Alzheimer's disease. We describe herein the investigation of disease-relevant small amyloid-β oligomers by mass spectrometry and ion mobility spectrometry, revealing functionally relevant structural attributes. In particular, we can show that amyloid-β oligomers develop in two distinct arrangements leading to either neurotoxic oligomers and fibrils or non-toxic amorphous aggregates. Comprehending the key-attributes responsible for those pathways on a molecular level is a pre-requisite to specifically target the peptide's tertiary structure with the aim to promote the emergence of non-toxic aggregates. Here, we show for two fibril inhibiting ligands, an ionic molecular tweezer and a hydrophobic peptide that despite their different interaction mechanisms, the suppression of the fibril pathway can be deduced from the disappearance of the corresponding structure of the first amyloid-β oligomers. eLife Sciences Publications, Ltd 2020-10-23 /pmc/articles/PMC7682991/ /pubmed/33095161 http://dx.doi.org/10.7554/eLife.59306 Text en © 2020, Lieblein et al http://creativecommons.org/licenses/by/4.0/ http://creativecommons.org/licenses/by/4.0/This article is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use and redistribution provided that the original author and source are credited.
spellingShingle Neuroscience
Lieblein, Tobias
Zangl, Rene
Martin, Janosch
Hoffmann, Jan
Hutchison, Marie J
Stark, Tina
Stirnal, Elke
Schrader, Thomas
Schwalbe, Harald
Morgner, Nina
Structural rearrangement of amyloid-β upon inhibitor binding suppresses formation of Alzheimer’s disease related oligomers
title Structural rearrangement of amyloid-β upon inhibitor binding suppresses formation of Alzheimer’s disease related oligomers
title_full Structural rearrangement of amyloid-β upon inhibitor binding suppresses formation of Alzheimer’s disease related oligomers
title_fullStr Structural rearrangement of amyloid-β upon inhibitor binding suppresses formation of Alzheimer’s disease related oligomers
title_full_unstemmed Structural rearrangement of amyloid-β upon inhibitor binding suppresses formation of Alzheimer’s disease related oligomers
title_short Structural rearrangement of amyloid-β upon inhibitor binding suppresses formation of Alzheimer’s disease related oligomers
title_sort structural rearrangement of amyloid-β upon inhibitor binding suppresses formation of alzheimer’s disease related oligomers
topic Neuroscience
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7682991/
https://www.ncbi.nlm.nih.gov/pubmed/33095161
http://dx.doi.org/10.7554/eLife.59306
work_keys_str_mv AT liebleintobias structuralrearrangementofamyloidbuponinhibitorbindingsuppressesformationofalzheimersdiseaserelatedoligomers
AT zanglrene structuralrearrangementofamyloidbuponinhibitorbindingsuppressesformationofalzheimersdiseaserelatedoligomers
AT martinjanosch structuralrearrangementofamyloidbuponinhibitorbindingsuppressesformationofalzheimersdiseaserelatedoligomers
AT hoffmannjan structuralrearrangementofamyloidbuponinhibitorbindingsuppressesformationofalzheimersdiseaserelatedoligomers
AT hutchisonmariej structuralrearrangementofamyloidbuponinhibitorbindingsuppressesformationofalzheimersdiseaserelatedoligomers
AT starktina structuralrearrangementofamyloidbuponinhibitorbindingsuppressesformationofalzheimersdiseaserelatedoligomers
AT stirnalelke structuralrearrangementofamyloidbuponinhibitorbindingsuppressesformationofalzheimersdiseaserelatedoligomers
AT schraderthomas structuralrearrangementofamyloidbuponinhibitorbindingsuppressesformationofalzheimersdiseaserelatedoligomers
AT schwalbeharald structuralrearrangementofamyloidbuponinhibitorbindingsuppressesformationofalzheimersdiseaserelatedoligomers
AT morgnernina structuralrearrangementofamyloidbuponinhibitorbindingsuppressesformationofalzheimersdiseaserelatedoligomers